Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
J. Clin. Med. 2013, 2(4), 283-301; doi:10.3390/jcm2040283
Review

Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline

1,*  and 2
Received: 9 November 2013; in revised form: 26 November 2013 / Accepted: 28 November 2013 / Published: 17 December 2013
(This article belongs to the Special Issue Prevention and Treatment of Bone Metastases from Breast Cancer)
View Full-Text   |   Download PDF [227 KB, uploaded 17 December 2013]
Abstract: Bone loss is common in patients with breast cancer. Bone modifying agents (BMAs), such as bisphosphonates and denosumab, have been shown to reverse or stabilize bone loss and may be useful in the primary and metastatic settings. The purpose of this review is to provide clear evidence-based strategies for the management of bone loss and its symptoms in breast cancer. A systematic review of clinical trials and meta-analyses published between 1996 and 2012 was conducted of MEDLINE and EMBASE. Reference lists were hand-searched for additional publications. Recommendations were developed based on the best available evidence. Zoledronate, pamidronate, clodronate, and denosumab are recommended for metastatic breast cancer patients; however, no one agent can be recommended over another. Zoledronate or any oral bisphosphonate and denosumab should be considered in primary breast cancer patients who are postmenopausal on aromatase inhibitor therapy and have a high risk of fracture and/or a low bone mineral density and in premenopausal primary breast cancer patients who become amenorrheic after therapy. No one agent can be recommended over another. BMAs are not currently recommended as adjuvant therapy in primary breast cancer for the purpose of improving survival, although a major Early Breast Cancer Cooperative Trialists’ Group meta-analysis is underway which may impact future practice. Adverse events can be managed with appropriate supportive care.
Keywords: bone modifying agent; bisphosphonate; bone metastases; bone mineral density; breast cancer; adjuvant therapy; clinical practice guideline; systematic review bone modifying agent; bisphosphonate; bone metastases; bone mineral density; breast cancer; adjuvant therapy; clinical practice guideline; systematic review
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Paterson, A.H.G.; Shea-Budgell, M.A. Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline. J. Clin. Med. 2013, 2, 283-301.

AMA Style

Paterson AHG, Shea-Budgell MA. Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline. Journal of Clinical Medicine. 2013; 2(4):283-301.

Chicago/Turabian Style

Paterson, Alexander H.G.; Shea-Budgell, Melissa A. 2013. "Bone Health in Patients with Breast Cancer: Recommendations from an Evidence-Based Canadian Guideline." J. Clin. Med. 2, no. 4: 283-301.

J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert